From advances in mitral and tricuspid valve interventions to long-term outcomes following TAVI, we highlight some of the key studies set to be presented in London.

PCR London Valves 2026 takes place on 22–24 November, bringing together international experts to explore the latest developments in structural and valvular heart interventions. This year’s program features a series of late-breaking trials and hotline presentations, offering new insights into emerging transcatheter technologies, procedural strategies, and longer-term clinical outcomes.
Ahead of the meeting, we highlight seven studies to look out for.
Don’t miss out on hearing about our latest peer-reviewed articles, expert opinions, conference news, podcasts and more.
EXPLORE MR: A novel approach to mitral valve repair
The EXPLORE MR study, presented by Ulrich Schaefer, will explore transcatheter posterior leaflet restoration as a potential treatment approach for mitral regurgitation (MR). As transcatheter options for patients with mitral valve disease continue to expand, the study could provide important insights into the feasibility and potential clinical applications of this approach.
TARGET: Six-month outcomes with the Cardiovalve system
Georg Nickenig will present six-month results from the TARGET study, evaluating the safety and performance of the Cardiovalve transcatheter tricuspid valve replacement (TTVR) system. With increasing interest in catheter-based treatment for severe tricuspid regurgitation, the findings will contribute to the growing evidence base for emerging replacement technologies.
VIVA: Five-year outcomes of TAVI versus surgery
Long-term outcomes remain central to treatment decisions in patients undergoing aortic valve replacement. Marisa Avvedimento will present five-year results from the VIVA trial, comparing transcatheter aortic valve replacement (TAVR) with surgical aortic valve replacement in patients with small aortic annuli.
Previous findings demonstrated no statistically significant differences in key valve hemodynamic or clinical outcomes between TAVR and surgery at two years. The forthcoming five-year results will provide further insights into the longer-term comparative outcomes of these approaches in this anatomically challenging population.
TRILUMINATE, Tri.FR and TRIC-I-HF: Evaluating tricuspid interventions
Thomas Stocker will present a meta-analysis of the TRILUMINATE, Tri.FR and TRIC-I-HF trials, bringing together evidence on transcatheter tricuspid interventions. Previous studies have demonstrated improvements in tricuspid regurgitation severity and patient-reported outcomes, while findings from TRIC-I-HF have suggested potential benefits for heart failure-related clinical outcomes. The analysis could provide further insights into the role of transcatheter intervention and help inform patient selection.
PARADIGM: Early outcomes following paravalvular leak closure
Ignacio Cruz-Gonzalez will present 30-day outcomes from the PARADIGM study, investigating transcatheter paravalvular leak closure. Paravalvular leaks remain an important complication following valve replacement, and the study will provide additional evidence on early outcomes following catheter-based treatment.
ReTAVI: One-year outcomes following repeat TAVI
As the number of patients living with transcatheter heart valves increases, managing valve dysfunction and repeat interventions is becoming increasingly important. Radoslaw Parma will present the first prospective one-year outcomes from the ReTAVI registry, offering insights into the clinical outcomes of repeat TAVI procedures.
TRAFIC-PTA: Optimizing vascular access for TAVI
Flavio Luciano Ribichini will present findings from the randomized TRAFIC-PTA trial, comparing intravascular lithotripsy with percutaneous transluminal angioplasty for transfemoral access during TAVI. The findings could help inform strategies for managing challenging vascular anatomy and facilitating transfemoral interventions.
Looking ahead
Beyond these studies, the program includes new evidence on transcatheter mitral valve replacement, tricuspid valve replacement, valve durability, and outcomes in patients with complex aortic anatomy.
The late-breaking trials and hotline sessions at PCR London Valves 2026 will provide an opportunity to examine how emerging technologies and accumulating clinical evidence may influence the future management of structural heart disease.
Follow touchCARDIO for the latest news, trial results, and expert insights from PCR London Valves 2026.
Cite: PCR London Valves 2026: Late-breaking trials and hotlines to look out for. touchCARDIO. November 19 2026.
Disclosure: No funding was received in the publication of this article. This content has been developed independently by Touch Medical Media for touchCARDIO, utilizing AI as an editorial tool (Claude (Sonnet 5) [Large language model] https://claude.ai). No funding was received in the publication of this article.
Editor: Nicola Cartridge, Director of Content
touchCARDIO coverage of PCR London Valves 2026: This content has been developed independently by Touch Medical Media for touchCARDIO. It is not affiliated with PCR London Valves.

